![Curasight: Management remains confident on its strategy as new financing plan is launched](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/b1071161-b901-4fc5-ae33-33cc74450ee6.png)
Curasight
HC Andersen Capital receives payment from Curasight for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreLatest research
Analyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
![Curasight: Management remains confident on its strategy as new financing plan is launched](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/b1071161-b901-4fc5-ae33-33cc74450ee6.png)
BioStock: Curasight CEO comments on capital raise and milestone
Curasight to present at HC Andersen Capital
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
PREMIUM account
Curasight: Notice of Extraordinary General Meeting
Curasight A/S resolves on directed issues and a loan facility
Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer
BioStock: Curasight committed to progressing pipeline
Redeye: Curasight Q1 - Moving forward
Curasight: Interim report Q1 2024
BioStock: Curasight gets green light from EMA in phase II prostate cancer trial
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients
![Curasight (one-pager): Halving of market implied likelihood of succes looks exaggerated](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/75b7c302-48f4-4317-8fc2-347e9e556a2d.png)
Curasight (one-pager): Halving of market implied likelihood of succes looks exaggerated
Curasight announces change in the Board of Directors
Resolutions of the Annual General Meeting 2024 of Curasight A/S
![HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/06aef4ac-f94b-407d-ac4d-dffe67b0f7a5.png)